For indispensable reporting on the coronavirus crisis, the election, and more, subscribe to the Mother Jones Daily newsletter.





The White House today lifted a longstanding restriction on medical marijuana research, giving a green light to a growing group of mainstream scientists who are interested in investigating the potential health benefits of pot. Such research will no longer have to undergo review by the Public Health Service, a process that is ostensibly meant to ensure the use of scientifically valid clinical trials, but in practice has served as a barrier to launching studies. A bipartisan group of lawmakers, and even opponents of legalization, had called for the requirement to be lifted.

“This announcement is a pretty big deal,” says Christopher Brown, a spokesperson for Americans for Safe Access, a group that advocates for access to pot for medical research. “You have a lot of interest in experimental research on medical cannabis and this shows that you are starting to see policies aligned with that.”

The announcement comes a few months after US Surgeon General Vivek Murthy signaled the federal government’s shifting thinking on medical pot, telling CBS This Morning that preliminary data shows that “marijuana can be helpful” for some medical conditions.

Still, Americans for Safe Access is calling for the feds to loosen restrictions even more. Numerous startup companies are interested in capitalizing on the medical benefits of pot, but scientists who want to use marijuana for research currently must obtain it from a DEA-approved grow facility, a process that can take a year or longer if they need specific cannabis strains. And marijuana remains classified under Schedule 1 of the Controlled Substances Act, a category reserved for drugs that supposedly have no medical benefit.